Investor Relations (IR) Questions: Galena Biopharma GALE
Click here to return to the biotech IRQ Index
Answers received: February 2013
1) When is the last time GALE raised cash through an offering (diluted)?
The last offering of common stock was on Dec.18th as evidenced on the Company’s News page:
http://www.galenabiopharma.com/news
2) How much cash (not cash equivalents) does GALE have?
The last reported cash from Q3, 2012 was $15mm. With the financing in December, pro forma cash is approximately $40 not including the Q4 burn. These numbers can always be found on the Company’s quarterly statements, listed here:
http://investors.galenabiopharma.com/sec.cfm?Doc&Year=
3) What and approximately when is the next known catalyst?
On the Company’s homepage, there is a link to the corporate presentation and on slide 29 they list their upcoming milestones. www.galenabiopharma.com
The next major milestone will be the initiation of enrollment in the combination study with Herceptin which is expected in the first half of this year. The Company will also be presenting Phase 1 data on their Folate Binding Protein Asset in June at ASCO.
4) What is GALE's quarterly cash burn?
Galena’s cash burn is about $5-6 million per quarter.
5) Does GALE have an existing line of credit and if so how much can they draw against it?
No
1) When is the last time GALE raised cash through an offering (diluted)?
The last offering of common stock was on Dec.18th as evidenced on the Company’s News page:
http://www.galenabiopharma.com/news
2) How much cash (not cash equivalents) does GALE have?
The last reported cash from Q3, 2012 was $15mm. With the financing in December, pro forma cash is approximately $40 not including the Q4 burn. These numbers can always be found on the Company’s quarterly statements, listed here:
http://investors.galenabiopharma.com/sec.cfm?Doc&Year=
3) What and approximately when is the next known catalyst?
On the Company’s homepage, there is a link to the corporate presentation and on slide 29 they list their upcoming milestones. www.galenabiopharma.com
The next major milestone will be the initiation of enrollment in the combination study with Herceptin which is expected in the first half of this year. The Company will also be presenting Phase 1 data on their Folate Binding Protein Asset in June at ASCO.
4) What is GALE's quarterly cash burn?
Galena’s cash burn is about $5-6 million per quarter.
5) Does GALE have an existing line of credit and if so how much can they draw against it?
No